10.30- 12.00 | Parallel Session 1: Glutamate and corticostriatal dysfunction:
implications for schizophrenia and addiction Chairman: Dr John Krystal, USA
Speakers:
Dr Lars V. Kristiansen, Denmark “Abnormalities in the glutamate synapse in schizophrenia”
Prof. Trevor Robbins, UK “Stimulant dependence, compulsivity
and dopamine”
Prof. Andreas Heinz, Germany “Major psychoses and substance
abuse: evidence for common limbic alterations”
Dr John Krystal, USA “Opposing alterations in responses to NMDA receptor antagonists in schizophrenia and alcohol dependence:Implications for addiction risk and for treatment?” | Parallel Session 2: Nicotine abuse in schizophrenia
– molecular aspects Chairman: Prof. Georg Winterer, Germany Speakers:
Prof. Georg Winterer, Germany “Alpha4 nACh Genotype and Attentional Network Dysfunction - Implications for Nicotine Dependence in Schizophrenia”
Prof. Sherry Leonard, USA “Nicotine addiction in schizophrenia:
self medication?”
Dr Ingo Vernaleken, Germany “PET Studies of Dopaminergic
Systems in Nicotine Dependence and Schizophrenia”
Prof. Dr. Dan Rujescu, Germany “Variants in the CHRNA5-
CHRNA3- CHRNB4 gene cluster are associated with CHRNA5 gene expression and nicotine dependence in three large independent German cohorts” | Parallel Session 3: Stimulants
Chairman: Dr Paul Fletcher, UK
Speakers:
Dr Isabelle Boileau, Canada “Amphetamine sensitization in man”
Dr Paul Fletcher, UK “Ketamine-induced psychoses”
Dr Graham Murray, UK “Cognition in Parkinson’s disease psychosis”
Prof. Nori Takei, Japan “Mechanisms underlying methamphetamine psychoses”
Dr Tomáš Pálenièk, Czech Republic “From early to present use of psychedelic drugs such as LSD in research and psychiatry”
|
12.00 – 13.15 | Pfizer Satellite Symposium: The Links between Smoking and Psychiatric Disease: What can be done to help? Chairman: Prof. Wolfgang Fleischhacker, Austria Speakers:
Prof. Georg Winterer, Germany “An Overview of Smoking and Psychiatric Disease”
Dr Hans Rollema, Pfizer Groton, USA “The Mechanisms of Nicotine Addiction and Approaches to Overcome it”
Prof. Henri-Jean Aubin, France “Current Approaches to Smoking Cessation in Patients with Psychiatric Disease”
Prof. Torgny H. Svensson, Sweden “Future Approaches to Smoking Cessation in Patients with Psychiatric Disease” | | |
14.00 – 15.30 | Parallel Session 4: Two faces of Dopamine Chairman: Prof. Anissa Abi-Dargham, USA Speakers:
Prof. Anissa Abi-Dargham, USA “Dopamine alterations in comorbidity”
Dr Christoph Kellendonk, USA “Excess dopamine D2 receptors in the striatum affect cognition and motivation in mice”
Dr Eleanor Simpson, USA “Modelling endophenotypes for
addiction and schizophrenia in COMT over-expressing mice”
Prof. Anthony Grace, USA “Schizophrenia, stress, and drug abuse: common pathophysiological mechanisms” | Parallel Session 5: Hallucinogenic drugs and psychosis – psychopathology and brain mechanisms Chairman: Prof. Euphrosyne Gouzoulis-Mayfrank, Germany Speakers:
Prof. Franz X. Vollenweider, Switzerland “Spatiotemporal brain imaging of visual hallucinations induced by the 5-HT2A agonist psilocybin in humans”
Prof. Bill Deakin, UK “Glutamate and the origin and progression of psychosis”
Dr Garry D. Honey, UK “Applying pharmalogial models of psychosis to understand cognitive and physiological mechanisms associated with schizophrenia”
Dr Joerg Daumann, Germany “Attention Processes and its Brain Mechanisms in the Human 5-HT2A Agonist and NMDA Anta-gonist Model of Psychosis” | Parallel Session 6: Cannabis concerns: the experimental and sociological background Chairman: Prof. Don Linszen, The Netherlands Speakers:
Prof. Roger Pertwee, UK “The endocannabinoid system”
Dr David Potter, UK “Increasing Cannabis potency"
Prof. Valerie Curran, UK “Differential effects on THC and CBD in “normal” cannabis smokers”
Dr Paul Morrison, UK “Acute effects of Intravenous THC”
Dr Judith Allardyce, The Netherlands “Epidemiological Studies of Cannabis and Psychosis” |
16.00 – 17.30 | Parallel Session 7: Cannabis use and the presentation and outcome of psychosis Chairman: Prof. Robin Murray, UK Speakers:
Prof. Philip McGuire, UK “A functional MRI study of the effects of cannabis”
Prof. Don Linszen, The Netherlands “Clinical studies of cannabis use”
Dr Marta di Forti, UK “Skunk and Psychosis in South East London”
Dr Cathy Fernandes, UK “Modelling the effects of cannabis in adolescent mice”
Dr Wiepke Cahn., The Netherlands “Cannabis use and progression of brain changes”
| Parallel Session 8: Clozapine and comorbid substance abuse in schizophrenia: Mode of action and novel leads Chairman: Prof. Torgny H. Svensson, Sweden Speakers:
Prof. Torgny H. Svensson, Sweden “Significance of alpha2 adrenoceptor blockade and NET inhibition for antipsychotic drug effects”
Dr Svante Nyberg, Sweden “A translational perspective on quetiapine - clinical utility”
Prof. Alan I. Green, USA “A Translational Perspective on Clozapine: Clinical Utility”
Prof. Helen M. Pettinati, USA “A double-blind, placebocontrolled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism” | Parallel Session 9: Alcohol Chairman: Prof. Andreas Heinz, Germany and Prof. Gunter Schumann, UK Speakers:
Prof. Gunter Schumann, UK “Genetic findings in alcoholism - role of the glutamatergic system”
Prof. Rainer Spanagel, Germany “Metabotropic glutamate receptors and alcohol seeking and relapse”
Dr Florian Schlagenhauf, Germany “Reward system dysfunction in alcoholism and schizophrenia” |
